The Effect of Plasminogen Activator Inhibitor-1 −675 4G/5G Polymorphism on PAI-1 Gene Expression and Adipocyte Differentiation

Abstract

Obesity is a complex, multifactorial chronic disease frequently associated with cardiovascular risks, hypertriglyceridemia, low high-density lipoprotein-cholesterol, high blood pressure, and the insulin resistance that appears to be central to the pathogenesis of Type II diabetes. Plasminogen activator inhibitor-1 expression induced in differentiating adipose tissue, but its role in adipogenesis and obesity is poorly understood. Circulating plasminogen activator inhibitor-1 levels are elevated at an early stage of impaired glucose tolerance, resulting in diabetes and metabolic syndrome. Plasminogen activator inhibitor-1 levels are also significantly elevated in the plasma of obese individuals and in adipose tissues of obese mice and humans. Some investigators proposed that the −675 4G/5G polymorphism in plasminogen activator inhibitor-1 promoter caused overexpression of this gene and predisposed carriers to obesity. In this study, we investigated the role of −675 4G/5G polymorphism in plasminogen activator inhibitor-1 promoter in the expression of this gene and the contribution of plasminogen activator inhibitor-1 to adipogenesis. Using a dualluciferase promoter assay, we determined that the −675 4G/5G polymorphism contributes significantly to overexpression of plasminogen activator inhibitor-1 in the course of adipogenesis. The antidiabetic agents troglitazone and ciglitazone inhibited reporter gene expression driven by wild-type and −675 4G/5G mutant promoter, as well as the expression of endogenous plasminogen activator inhibitor-1, indicating that suppression of plasminogen activator inhibitor-1 expression may contribute to antidiabetic effects of these agents. The results indicate that absence of plasminogen activator inhibitor-1 in adipocytes may protect the cells against insulin resistance by promoting glucose uptake and adipocyte differentiation via a decrease in the peroxisome proliferator activated receptor-gamma expression that modulates the adipocyte differentiation.

Keywords

plasminogen activator-1 human umbilical cord vein endothelial cells troglitazone ciglitazone

References

Alessi MC , Peiretti F. , Morange P. , Henry M. , Nalbone G. , Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes. 1997;46:860-867.

Asplund-Carlson A. , Hamsten A. , Wiman B. , Carlson LA Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normal and hypertriglyceridaemic men. Diabetologia . 1993;36:817-825.

Combs TP , Pajvani UB , Berg AH , et al. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology. 2004;145:367-383.

Estelles A. , Dalmau J. , Falco C. , et al. Plasma PAI-1 levels in obese children-effect of weight loss and influence of PAI-1 promoter 4G/5G genotype. Thromb Haemost . 2001; 86:647-652.

Doggen CJM , Bertina RM , Cats VM , Reitsma PH , Rosendaal FR The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is strongly associated with obesity. Diabetologia.2002 ;45:584-587.

Lehmann JM , Moore LB , Smitholiver TA , Wilkison WO , Willson TM , Kliewer SA An antidiabetic thiazolidinedione is a high-affinity ligand for peroxisome-proliferator activated receptor gamma (PPAR-gamma). J Biol Chem. 1995;270:12953-12956.

Issemann I. , Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature (Lond). 1990;347:645-650.

Akar N. , Akar E. , Yilmaz E. , Deda G. Plasminogen activator inhibitor-1 4G/5G polymorphism in Turkish children with cerebral infarct and effect on factor V 1691 A mutation. J Child Neurol. 2001;16:294-295.

Berberoğlu M. , Evliyaoğlu O. , Adiyaman P. , et al. Plasminogen activator inhibitor-1 (PAI-1) gene polymorphism (-675 4G/5G) associated with obesity and vascular risk in children. J Pediatr Endocrinol Metab. 2006; 19:741-748.

10.

Liang X. , Kanjanabuch T. , Mao S-L. , et al. Plasminogen activator inhibitor-1 modulates adipocyte differentiation . Am J Physiol Endocrinol Metab. 2005;10:1152-1153.

11.

Lambert V. , Munaut C. , Noel A. , et al. Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. FASEB J. 2001;15:1021-1027.

12.

Deng X. , Li H. , Tang YW Cytokine expression in respiratory syncytial virus-infected mice as measured by quantitative reverse-transcriptase PCR. J Virol Methods . 2003;107:141-146.

13.

Dong J. , Fujii S. , Li H. , et al. Interleukin-6 and mevastatin regulate plasminogen activator inhibitor-1 through CCAAT/enhancer-binding protein-δ. Arterioscler Thromb Vasc Biol. 2005;25:1078-1084.

14.

Debrock S. , Declerck PJ Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms. Biochim Biophys Acta. 1997;1337:257-266.

15.

Akar N. , Yilmaz E. , Akar E. , Avcu F. , Yalcin A. , Cin S. Effect of plasminogen activator inhibitor-1 4G/5G polymorphism in Turkish deep vein thrombotic patients with and without FV1691G-A. Thromb Res. 2000;97:227-230.

16.

Haffner SM , D'Agostino R. Jr , Mykkanen L. , et al. Insulin sensitivity in subjects with type 2 diabetes relationship to cardiovascular risk factors: the insulin resistance atherosclerosis study . Diabetes Care. 1999;22:562-568.

17.

Cigolini M. , Targher G. , Seidell JC , et al. Relationships of plasminogen activator inhibitor-1 to anthropometry, serum insulin, triglycerides and adipose tissue fatty acids in healthy men. Atherosclerosis . 1994;106:139-147.

18.

Landin K. , Stigendahl L. , Eriksson E. , et al. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism. 1990;39:1044-1048.

19.

Sawdey MS , Loskutoff DJ Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest. 1991;88:1346-1353.

20.

Lin FT , Lane MD CCAAT/enhancer binding protein alpha is sufficient to initiate the 3T3-L1 adipocyte differentiation program. Proc Natl Acad Sci U S A. 1994; 91:8757-8761.

21.

Liang X. , Kanjanabuch T. , Mao S. , et al. Plasminogen activator inhibitor-1 modulates adipocyte differentiation . Am J Physiol Endocrinol Metab. 2005;290: E103-E113.

22.

Rosen ED , Hsu CH , Wang X. , et al. C/EBPα induces adipogenesis through PPARγ: a unified pathway. Genes Dev. 2002;16:22-26.

23.

Rosen ED , Walkey CJ , Puigserver P. , Spiegelman BM Transcriptional regulation of adipogenesis. Genes Dev. 2000;14:1293-1307.

24.

Wu Z. , Rosen ED , Brun R. , et al. Cross-regulation of C/EBP alpha and PPAR gamma controls the transcriptional pathway of adipogenesis and insulin sensitivity. Mol Cell. 1999;3:151-158.

25.

Evans RM , Barish GD , Wang YX PPARs and the complex journey to obesity. Nat Med. 2004;10:355-361.

26.

Aktas H. , Cai H. , Cooper GM Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1. Mol Cell Biol . 1997;17:3850-3857.

27.

Kudo M. , Sugawara A. , Uruno A. , Takeuchi K. , Ito S. Transcription suppression of peroxisome proliferator-activated receptor γ2 gene expression by tumor necrosis factor α via an inhibition of CCAAT/enhancer-binding protein δ during the early stage of adipocyte differentiation. Endocrinology. 2004;145:4948-4956.

28.

Picard F. , Auwerx J. PPAR (gamma) and glucose homeostasis. Annu Rev Nutr . 2002;22:167-197.

29.

Barroso I. , Gurnell M. , Crowley VE , et al. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature. 1999;402:880-883.

30.

He W. , Barak Y. , Hevener A. , et al. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle . Proc Natl Acad Sci USA. 2003;100:15712-15717.

31.

Oishi K. , Ohkura N. , Amagai N. , Ishida N. Involvement of circadian clock gene Clock in diabetes-induced circadian augmentation of plasminogen activator inhibitor-1 (PAI-1) expression in the mouse heart . FEBS Lett. 2005;579:3555-3559.